STAT6 mediates apoptosis of human coronary arterial endothelial cells by interleukin-13

Hypertension Research

Volumn 31, Issue 3, 2008, Pages 535-541

  Nishimura, Yuki ^a   Nitto, Takeaki ^a   Inoue, Teruo ^a   Node, Koichi ^a  

^a SAGA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Cell growth; Endothelial cell; Interleukin 13; STAT6

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 4; MESSENGER RNA; STAT6 PROTEIN; VASCULOTROPIN;

APOPTOSIS; ARTERY ENDOTHELIUM; ARTICLE; CELL ASSAY; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CORONARY ARTERY; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INHIBITION KINETICS; ISCHEMIC HEART DISEASE; PATHOPHYSIOLOGY; PROTEIN DEPLETION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TH2 CELL;

APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CORONARY VESSELS; DOWN-REGULATION; ENDOTHELIAL CELLS; HUMANS; INTERLEUKIN-13; INTERLEUKIN-4; RNA, MESSENGER; RNA, SMALL INTERFERING; STAT6 TRANSCRIPTION FACTOR; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 42649128112     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.535     Document Type: Article

References (36)

1. Hershey GK: IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol 2003; 111: 677-691.
2. Kotowicz K, Callard RE, Friedrich K, Matthews DJ, Klein N: Biological activity of IL-4 and IL-13 on human endothelial cells: functional evidence that both cytokines act through the same receptor. Int Immunol 1996; 8: 1915-1925.
3. Shimoda K, Deursen J, Sangster MY, et al: Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 1996; 380: 630-633.
4. Takeda K, Kamanaka M, Tanaka T, Kishimoto T, Akira S: Impaired IL-13-mediated functions of macrophages in STAT6-deficient mice. J Immunol 1996; 157: 3220-3222.
5. Palmer-Crocker RL, Hughes CC, Pober JS: IL-4 and IL-13 activate the JAK2 tyrosine kinase and Stat6 in cultured human vascular endothelial cells through a common pathway that does not involve the γc chain. J Clin Invest 1996; 98: 604-609.
6. Gooch JL, Christy B, Yee D: STAT6 mediates interleukin-4 growth inhibition in human breast cancer cells. Neoplasia 2002; 4: 324-331.
7. Obiri NI, Hillman GG, Haas GP, Sud S, Puri RK: Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J Clin Invest 1993; 91: 88-93.
8. Toi M, Bicknell R, Harris AL: Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res 1992; 52: 275-279.
9. Topp MS, Papadimitriou CA, Eitelbach F, et al: Recombinant human interleukin 4 has antiproliferative activity on human tumor cell lines derived from epithelial and nonepithelial histologies. Cancer Res 1995; 55: 2173-2176.
10. Aoudjehane L, Podevin P, Scatton O, et al: Interleukin-4 induces human hepatocyte apoptosis through a Fas-independent pathway. FASEB J 2007; 21: 1433-1444.
11. Kim J, Cheon IS, Won YJ, Na HJ, Kim YM, Choe J: IL-4 inhibits cell cycle progression of human umbilical vein endothelial cells by affecting p53, p21(Waf1), cyclin D1, and cyclin E expression. Mol Cells 2003; 16: 92-96.
12. Lee YW, Kuhn H, Hennig B, Toborek M: IL-4 induces apoptosis of endothelial cells through the caspase-3-dependent pathway. FEBS Lett 2000; 485: 122-126.
13. Volpert OV, Fong T, Koch AE, et al: Inhibition of angiogenesis by interleukin 4. J Exp Med 1998; 188: 1039-1046.
14. Mascareno E, El-Shafei M, Maulik N, et al: JAK/STAT signaling is associated with cardiac dysfunction during ischemia and reperfusion. Circulation 2001; 104: 325-329.
15. Nishimura Y, Inoue T, Nitto T, Morooka T, Node K: Increased interleukine-13 levels in patients with chronic heart failure. Int J Cardiol 2008 (in press).
16. Foteinos G, Afkal AR, Mandal K, Jahangiri M, Xu Q: Anti-heat shock protein 60 autoantibodies, induce atherosclerosis in apolipoprotein E-deficient mice via endothelial damage. Circulation 2005; 112: 1206-1213.
17. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
18. Yla-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J: Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 2007; 49: 1015-1026.
19. Liu Y, Cox SR, Morita T, Kourembanas S: Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res 1995; 77: 638-643.
20. Seghezzi G, Patel S, Ren CJ, et al: Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol 1998; 141: 1659-1673.
21. Nishimura Y, Nitto T, Inoue T, Node K: IL-13 attenuates vascular tube formation via JAK2-STAT6 pathway. Circ J 2008; 72: 469-475.
22. Evans PC, Kilshaw PJ: Interleukin-13 protects endothelial cells from apoptosis and activation: association with the protective genes A20 and A1. Transplantation 2000; 70: 928-934.
23. Grehan JF, Levay-Young BK, Fogelson JL, Francois-Bongarcon V, Benson BA, Dalmasso AP: IL-4 and IL-13 induce protection of porcine endothelial cells from killing by human complement and from apoptosis through activation of a phosphatidylinositide 3-kinase/Akt pathway: J Immunol 2005; 175: 1903-1910.
24. Haas CS, Amin MA, Allen BB, et al: Inhibition of angio-genesis by interleukin-4 gene therapy in rat adjuvant-induced arthritis. Arthritis Rheum 2006; 54: 2402-2414.
25. Bennett BL, Cruz R, Lacson RG, Manning AM: Interleukin-4 suppression of tumor necrosis factor α-stimulated E-selectin gene transcription is mediated by STAT6 antagonism of NF-KB. J Biol Chem 1997; 272: 10212-10219.
26. Scatena M, Almeida. M, Chaisson ML, Fausto N, Nicosia RF, Giachelli CM: NF-KB mediates αcvβ3 integrin-induced endothelial cell survival. J Cell Biol 1998; 141: 1083-1093.
27. Grosjean J, Kiriakidis S, Reilly K, Feldmann M, Paleolog E: Vascular endothelial growth factor signaling in endothelial cell survival: a role for NFKB. Biochem Biophys Res Commun 2006; 340: 984-994.
28. Daniel S, Arvelo MB, Patel VI, et al: A20 protects endothelial cells from TNF-, Fas-, and NK-mediated cell death by inhibiting caspase 8 activation. Blood 2004; 104: 2376-2384.
29. Longo CR, Arvelo MB, Patel VI, et al: A20 protects from CD40-CD40 ligand-mediated endothelial cell activation and apoptosis. Circulation 2003; 108: 1113-1118.
30. Kip1 expression. Mol Cell Biol 1998; 18: 1996-2003.
31. Bouton LA, Ramirez CD, Bailey DP, et al: Costimulation with interleukin-4 and interleukin-10 induces mast cell apoptosis and cell cycle arrest: p53 and the mitochondrion. Exp Hematol 2004; 32: 1137-1145.
32. Bailey DP, Kashyap M, Mirmonsef P, et al: Interleukin-4 elicits apoptosis of developing mast cells via a Stat6-dependent mitochondrial pathway. Exp Hematol 2004; 32: 52-59.
33. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E: Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995; 1: 1024-1028.
34. Saleh M, Davis ID, Wilks AF: The paracrine role of tumour-derived mIL4 on tumour-associated endothelium. Int J Cancer 1997; 72: 664-672.
35. Griga T, Hebler U, Voigt E, Tromm A, May B: Interleukin-4 inhibits the increased production of vascular endothelial growth factor by peripheral blood mononuclear cells in patients with inflammatory bowel disease. Hepatogastroenterology 2000; 47: 1604-1607.
36. Matsumoto K, Ohi H, Kanmatsuse K: Interleukin-4 cooperates with interleukin-10 to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with minimal-change nephrotic syndrome. Am J Nephrol 1999; 19: 21-27.